We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Activists have accused a US drug company called Gilead Sciences of exploiting sex workers in Cambodia, Cameroon, Ghana and Nigeria during research into an AIDS drug called Viread. The protestors say that trials should stop because although some of the study participants are taking Viread, others receive pills with no medicinal value and could get infected by HIV.

Opponents of the trials say that the company intentionally provides inadequate information to the volunteers, because of a need to have data on infection rates of those not taking Viread. They are calling upon Gilead Sciences to cover lifetime costs of anyone who contracts HIV/AIDS during the study. But Gilead's research chief says its trials have been approved and that volunteers receive counselling, education and condoms. These, he says, will reduce the likelihood of them contracting HIV/AIDS.

Viread is already registered for use by people with HIV in the United States. Research has shown that the drug protected monkeys from a related virus, and researchers hope that it could be used as an AIDS 'prevention pill'.

Link to full news story in The Scotsman